ReviewCureus2024
Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Recent Advances in Material Basis for Co-treatment of Cardiovascular and Gastrointestinal Disorders.Chinese journal of integrative medicine · 2026Review
- Extra-Virgin Olive Oil Phenolics in IBD-Associated Vascular Risk.Molecules (Basel, Switzerland) · 2026Review
- Association of histologic and clinical activity with major adverse cardiovascular events in patients with inflammatory bowel disease: A cohort study.Journal of internal medicine · 2025Article
- Arrhythmogenic Implications of Inflammatory Bowel Disease: Its Mechanisms and Treatment Effects.Cureus · 2025Review
- Article
- The Vulnerable Vascular Network: Endothelial Dysfunction as a Central Driver of Intestinal Inflammation-A Systematic Review.Biomedicines · 2025Review
- Article
- Cellular and Molecular Mechanisms Explaining the Link Between Inflammatory Bowel Disease and Heart Failure.Cells · 2025Review
- Microbiota in Gut-Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease.Comprehensive Physiology · 2025Review
- Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives.Advances in therapy · 2025Review
- The Role of the Gut Microbiota in Heart Failure: Pathophysiological Insights and Future Perspectives.Medicina (Kaunas, Lithuania) · 2025Review
- Review
- The Role of Microbiome in Cardiovascular Health: Insights for Primary Care Interventions.Cureus · 2024Review
- Gut dysbiosis mediates the association between antibiotic exposure and chronic disease.Frontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract. Recent research indicates a significant link between IBD and cardiovascular disease (CVD), the leading cause of global morbidity and mortality. This review examines the association between IBD and CVD, emphasizing the role of the gut microbiome in this relationship. IBD patients have a higher risk of cardiovascular events, such as coronary artery disease, heart failure, and cerebrovascular incidents, primarily due to chronic systemic inflammation, genetic factors, and gut microbiota imbalance (dysbiosis). Dysbiosis in IBD increases intestinal permeability, allowing bacterial products to enter the bloodstream, which promotes inflammation and endothelial dysfunction, contributing to CVD. Understanding the gut microbiome's role in IBD and CVD suggests new therapeutic interventions. Modulating the microbiome through diet, probiotics, and fecal microbiota transplantation (FMT) are promising research avenues. These interventions aim to restore a healthy gut microbiota balance, potentially reducing inflammation and improving cardiovascular outcomes. Additionally, the review emphasizes the importance of regular cardiovascular risk assessments and personalized preventive measures in managing IBD patients. Such measures include routine monitoring of cardiovascular health, tailored lifestyle modifications, and early intervention strategies to mitigate cardiovascular risk. By integrating current knowledge, this review aims to improve understanding and management of the interconnected pathophysiology of IBD and CVD. This approach will ultimately enhance patient outcomes and provide a foundation for future research and clinical practice guidelines in this area.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.